Patents by Inventor Kusuki Nishioka
Kusuki Nishioka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170231966Abstract: An object is to find a substance which inhibits IL-2 production. IL-2 production can be inhibited by a compound represented by the following formula (I): wherein R1 to R4 and A are as defined in the present specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 2, 2017Publication date: August 17, 2017Applicant: AYUMI PHARMACEUTICAL CORPORATIONInventors: Toshihiro NAKAJIMA, Satoko ARATANI, Kusuki NISHIOKA, Hiroyuki AONO
-
Patent number: 9650351Abstract: An object is to find a substance which inhibits IL-2 production. IL-2 production can be inhibited by a compound represented by the following formula (I): wherein R1 to R4 and A are as defined in the present specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 19, 2014Date of Patent: May 16, 2017Assignee: AYUMI PHARMACEUTICAL CORPORATIONInventors: Toshihiro Nakajima, Satoko Aratani, Kusuki Nishioka, Hiroyuki Aono
-
Publication number: 20160046591Abstract: An object is to find a substance which inhibits IL-2 production. IL-2 production can be inhibited by a compound represented by the following formula (I): wherein R1 to R4 and A are as defined in the present specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 19, 2014Publication date: February 18, 2016Applicant: AYUMI PHARMACEUTICAL CORPORATIONInventors: Toshihiro NAKAJIMA, Satoko ARATANI, Kusuki NISHIOKA, Hiroyuki AONO
-
Patent number: 9200077Abstract: Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.Type: GrantFiled: January 27, 2011Date of Patent: December 1, 2015Assignee: AXIS, Inc.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Patent number: 8729027Abstract: Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.Type: GrantFiled: July 4, 2011Date of Patent: May 20, 2014Assignee: AXIS Inc.Inventor: Kusuki Nishioka
-
Publication number: 20130196980Abstract: A diagnostic agent and a diagnostic method for appropriately diagnosing fibromyalgia of a specific type, and a therapeutic agent for the aforesaid type include a diagnostic agent for fibromyalgia relating to an anti-voltage-gated potassium channel complex antibody (anti-VGKC complex antibody), said diagnostic agent containing a reagent for detecting the anti-VGKC complex antibody; a diagnostic method using the diagnostic agent; and a therapeutic agent for fibromyalgia relating to the anti-VGKC complex antibody. A diagnostic agent for fibromyalgia relating to an antibody against a voltage-gated potassium channel complex includes a reagent for detecting the antibody against the voltage-gated potassium channel complex; and a therapeutic agent for fibromyalgia relating to an antibody against voltage-gated potassium channel contains an effective amount of an anticonvulsant drug (gabapentine or clonazepam) as the active ingredient.Type: ApplicationFiled: October 4, 2011Publication date: August 1, 2013Applicant: AXIS INC.Inventors: Yoshihisa Yamano, Kusuki Nishioka
-
Publication number: 20130108637Abstract: Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.Type: ApplicationFiled: July 4, 2011Publication date: May 2, 2013Applicant: AXIS INC.Inventor: Kusuki Nishioka
-
Patent number: 8377444Abstract: A method for treatment of disease classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis, the method includes a step of administrating an agent containing an anti-Fas IgM antibody as an active ingredient.Type: GrantFiled: July 31, 2009Date of Patent: February 19, 2013Assignee: AXIS Inc.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Publication number: 20130034563Abstract: Methods for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or classified as grade 1 to 3 according to the Outerbridge classification of osteoarthritis, include administering to a subject in need thereof a therapeutically effective amount of treatment agents or preventive agents containing an anti-Fas IgM antibody as an active ingredient to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.Type: ApplicationFiled: January 27, 2011Publication date: February 7, 2013Applicant: AXIS INC.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Publication number: 20130011407Abstract: Pharmaceutical compositions for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis and methods of manufacturing same contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier with acidity of pharmaceutical compositions ranging from pH 4 to pH 9 to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.Type: ApplicationFiled: January 27, 2011Publication date: January 10, 2013Applicant: AXIS INC.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Publication number: 20130011416Abstract: Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.Type: ApplicationFiled: January 27, 2011Publication date: January 10, 2013Applicant: AXIS INC.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Publication number: 20110217387Abstract: A pharmaceutical composition for the treatment of fibromyalgia, which includes pilocarpine or a pharmacologically acceptable salt thereof. The pharmaceutical composition can be used as a novel therapeutic agent for fibromyalgia.Type: ApplicationFiled: May 15, 2009Publication date: September 8, 2011Applicant: AXIS, INC.Inventors: Kusuki Nishioka, Hiroshi Oka, Rieko Nohara
-
Publication number: 20110182915Abstract: A method for treatment of disease classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis, the method includes a step of administrating an agent containing an anti-Fas IgM antibody as an active ingredient.Type: ApplicationFiled: July 31, 2009Publication date: July 28, 2011Applicant: AXIS, INC.Inventors: Kusuki Nishioka, Kazuo Yudo
-
Publication number: 20110160434Abstract: A method for diagnosing or testing for fibromyalgia with a specific peptide in the blood as an indicator, as well as a method for effectively evaluating or assessing a fibromyalgia drug with the peptide as an indicator. A method for diagnosing or testing for fibromyalgia or for evaluating or assessing a fibromyalgia drug, by subjecting a patient's serum to peptide analysis using as an indicator (biomarker) a peptide that demonstrates a specific expression amount in the blood of a fibromyalgia patient.Type: ApplicationFiled: July 6, 2009Publication date: June 30, 2011Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Kusuki Nishioka, Tomohiro Kato, Hiroki Fujisawa
-
Patent number: 7923254Abstract: A method for studying, determining or evaluating a pharmacological action of a test substance, the method including subjecting the brain tissue of an SART stressed animal administered with the test substance to an expression proteome analysis, where expression changes of NSF (N-ethylmaleimide sensitive fusion protein), which is or is not modified after translation, in the SART stressed animal administered with the test substance as compared with an SART stressed animal to which a test substance is not administered is used as an index.Type: GrantFiled: September 5, 2007Date of Patent: April 12, 2011Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Kusuki Nishioka, Tomohiro Kato, Hiroki Fujisawa
-
Publication number: 20090280177Abstract: It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent salazosulfapyridine was administered to fibromyalgia patients. Unexpectedly, salazosulfapyridine was seen to be effective in fibromyalgia patients in whom neither the rheumatoid factor nor an immune disorder was detectable, in particular to relieve pain of enthesitis. Furthermore, salazosulfapyridine was also effective to alleviate enthesitis and to relieve pain in fibromyalgia. In addition, the combined use of salazosulfapyridine with a corticosteroid or a nonsteroidal anti-inflammatory agent potentiated the therapeutic effect of salazosulfapyridine in clinical patients to whom salazosulfapyridine alone was not effective enough.Type: ApplicationFiled: October 4, 2007Publication date: November 12, 2009Inventor: Kusuki Nishioka
-
Publication number: 20090272649Abstract: A method for studying, determining or evaluating a pharmacological action of a test substance, the method including subjecting the brain tissue of an SART stressed animal administered with the test substance to an expression proteome analysis, where expression changes of NSF (N-ethylmaleimide sensitive fusion protein), which is or is not modified after translation, in the SART stressed animal administered with the test substance as compared with an SART stressed animal to which a test substance is not administered is used as an index.Type: ApplicationFiled: September 5, 2007Publication date: November 5, 2009Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Kusuki Nishioka, Tomohiro Kato, Hiroki Fujisawa
-
Patent number: 7435547Abstract: A therapeutic agent for fibromyalgia containing an extract from inflamed tissue inoculated with vaccinia virus as an active ingredient, use of the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises administering a medicinal composition containing the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient to a patient. The therapeutic agent containing the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient is a novel therapeutic agent for fibromyalgia, no efficacious therapeutic agent for which has been known heretofore. Moreover, it is very useful as an effective drug having high safety with scarcely any side effects.Type: GrantFiled: May 24, 2007Date of Patent: October 14, 2008Assignees: Nippon Zoki Pharmaceutical Co., Ltd., Argenes, Inc.Inventor: Kusuki Nishioka
-
Publication number: 20080194038Abstract: It is intended to provide a method for studying, determining or evaluating a pharmacological effect such as an effect on fibromyalgia, an analgesic effect or an antistress effect of a test substance by administering the test substance to a SART stress-loaded animal and then subjecting the brain tissue to expression and proteome analysis. By conducting the expression and proteome analysis to examine how the test substance affects a change in protein expression occurring in the brain tissue of the SART stress-loaded animal, it is possible to search for a substance efficacious against fibromyalgia or painful diseases, an antistress agent and so on.Type: ApplicationFiled: March 6, 2006Publication date: August 14, 2008Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Kusuki Nishioka, Tomohiro Kato, Hiroki Fujisawa
-
Publication number: 20070218037Abstract: A therapeutic agent for fibromyalgia containing an extract from inflamed tissue inoculated with vaccinia virus as an active ingredient, use of the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises administering a medicinal composition containing the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient to a patient. The therapeutic agent containing the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient is a novel therapeutic agent for fibromyalgia, no efficacious therapeutic agent for which has been known heretofore. Moreover, it is very useful as an effective drug having high safety with scarcely any side effects.Type: ApplicationFiled: May 24, 2007Publication date: September 20, 2007Applicants: Nippon Zoki Pharmaceutical Co., Ltd., Argenes, Inc.Inventor: Kusuki Nishioka